At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of the Initial Prescription of Ketamine and Milnacipran Forin Depression in Patients With a Progressive Disease
In Brief
A Phase 3 clinical trial evaluating Ketamine, Milnacipran, and 1 other intervention for Depression. Completed, enrolled 42 participants across 9 sites.
Detailed Summary
KetaPal is a placebo-controlled randomized trial designed to demonstrate the antidepressant action of ketamine in palliative care situations. Half of participants will receive Ketamine and Milnacipran in combination, while the other half will receive a Placebo and Milnacipran in combination.
Study Details
Timeline
Interventions
One single perfusion of 0.5 mg/kg during 40 minutes at the beginning of the inclusion
One or two caps per day from the beginning of the inclusion. Milnacipran dosage depending of glomerular filtration rate of patient, during 16 days (doses of 25 or 50 mg or 100mg per day)
One single perfusion during 40 minutes at the beginning of the inclusion